|
1 Crowley P. Prophylactic corticosteroids for preterm birth [J]. Cochrane Database Syst Rev, 2000, CD000065.
|
|
2 Crowther CA, Harding J. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease[J]. Cochrane Database Syst Rev, 2003, CD003935.
|
|
3 Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants[J]. Cochrane Database Syst Rev, 2000, CD001079.
|
|
4 Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants[J]. Cochrane Database Syst Rev, 2000, CD000511.
|
|
5 Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants[J]. Cochrane Database Syst Rev, 2001, CD000510.
|
|
6 Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome[J]. Cochrane Database Syst Rev, 2001, CD000144.
|
|
7 Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants[J]. Cochrane Database Syst Rev, 2000, CD001149.
|
|
8 Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome[J]. Cochrane Database Syst Rev, 2007, CD006069.
|
|
9 Henderson－Smart DJ, Steer P. Methylxanthine treatment for apnoea in preterm infants[J]. Cochrane Database Syst Rev, 2001, CD000140.
|
|
10 Aranda JV, Gorman W, Bergsteinsson H, et al. Efficacy of caffeine in treatment of apnea in the low－birth－weight infant[J]. J Pediatr, 1977, 90: 467－472.
|
|
11 Kitchen WH, Doyle LW, Ford GW, et al. Cerebral palsy in very low birth weight infants surviving to 2 years with modern neonatal intensive care[J]. Am J Perinatol, 1987, 4: 29－35.
|
|
12 Hoecker C, Nelle M, Poeschl J, et al. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants[J]. Pediatrics, 2002, 109: 784－787.
|
|
13 Washington, DC: Food and Drug Administration. New drug application: CAFCIT (NDA) 02073[R]. 2000, 10－13.
|
|
14 Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2006, 354: 2112–2121.
|
|
15 Schmidt B, Roberts RS, Davis P, et al. Long term effects of caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2007, 357: 1893－1902.
|
|
16 Saugstad OD. Bronchopulmonary dysplasia－oxidative stress an anti－oxidants[J]. Semin Neonatol, 2003, 8: 39－49.
|
|
17 Tin W, Milligan DW, Pennefather P, et al. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation[J]. Arch Dis Child, 2001, 84: F106－110.
|
|
18 Chow L, Wright KW, Sola S. Can changes in clinical practice decrease the incidence of severe retinopathy in very low birth weight infants[J]? Pediatrics, 2003, 111: 339－345.
|
|
19 Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: A national survey of recent practices[J]. J Perinatol, 2004, 24: 164－168.
|
|
20 Sun SC. Relation of target SpO2 levels and clinical outcome in ELBW infants on supplemental oxygen[J]. Pediatr Res, 2002, 51: A350.
|
|
21 Poets C, Arand J, Hummler H, et al. Retinopathy of prematurity: A comparison between two centers aiming for different pulse oximetry saturation levels[J]. Biol Neonate, 2003, 84: A267.
|
|
22 Tin W, Wariyar U. Giving small babies oxygen: 50 years of uncertainty[J]. Semin Neonatol, 2002, 7: 361－367.
|
|
23 Silverman WA. A cautionary tale about supplemental oxygen: The albatross of neonatal medicine[J]. Pediatrics, 2004, 113: 394－396.
|
|
24 Kang JL, Park W, Pack IS, et al. Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor－kappa B and inflammation[J]. J Appl Physiol, 2002, 92: 795－801.
|
|
25 Ballard PL, Gonzales LW, Godinez RI, et al. Surfactant composition and function in a primate model of infant chronic lung disease: Effect of inhaled nitric oxide[J]. Pediatr Res, 2006, 59: 157－162.
|
|
26 McCurnin DC, Pierce RA, Chang LY, et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease[J]. Am J Physiol Lung Cell Mol Physiol, 2005, 288: L450－459.
|
|
27 Finer N, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term[J]. Cochrane Database Syst Rev, 2006, CD000339.
|
|
28 Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants[J]. Cochrane Database Syst Rev, 2007, CD000509.
|
|
29 Kinsella JP, WalshWF, Bose CL, et al. Inhaled nitric oxide in premature neonates with severe hypoxemic respiratory failure: A randomised controlled trial[J]. Lancet, 1999, 354: 1061－1065.
|
|
30 The Franco－Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: A randomised controlled trial[J]. Lancet, 1999, 354: 1066－1071.
|
|
31 Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants[J]. Arch Dis Child, 1997, 77: F185－190.
|
|
32 Field D, Elbourne D, Truesdale A, et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: The INNOVO multicentre randomised controlled trial[J]. Pediatrics, 2005, 115: 926－936.
|
|
33 Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure[J]. N Engl J Med, 2005, 353: 13－22.
|
|
34 Schreiber MD, Gin－Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome[J]. N Engl J Med, 2003, 349: 2099－2107.
|
|
35 Ballard RA, Truog WE, Cnann A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation[J]. N Engl J Med, 2006, 355: 343－353.
|
|
36 Mercier J, Hummler H, Dummeyer X, et al. Inhaled nitric oxide (iNO) for prevention of bronchopulmonary dysplasia (BPD) in preterm infants[J]. The EUNO Trial. EPAS, 2009, 3212－3215.
|
|
37 Halliday HL, Ehrenkranz RA, Doyle LW. Early (<96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants[J]. Cochrane Database Syst Rev, 2003, (1): CD001146.
|
|
38 Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants[J]. Cochrane Database Syst Rev, 2003, (1): CD001144.
|
|
39 Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants[J]. Cochrane Database Syst Rev, 2003, (1): CD001145.
|
|
40 American Academy of Pediatrics, Committee on Fetus and Newborn, Canadian Pediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants[J]. Pediatrics, 2002, 109: 330－338.
|
|
41 Halliday HL. Guidelines on neonatal steroids. Prenat Neonat Med 2001, 6: 371－373.
|
|
42 Merz U, Kusenbach G, Hausler M. Inhaled budesonide in ventilator－dependent preterm infants: A randomised double－blind pilot study[J]. Biol Neonate, 1999, 75: 46－53.
|
|
43 Shah V, Ohlsson A, Halliday HL, et al. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates[J]. Cochrane Database Syst Rev, 2007, CD001969.
|
|
44 Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates[J]. Cochrane Database Syst Rev, 2003, CD002058.
|
|
45 Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely－low－birth infants[J]. N Engl J Med, 1999, 340: 1962－1968.
|
|
46 Wardle SP, Hughes A, Chen S, et al. Randomised controlled trial of vitamin A supplementation in preterm infants to prevent chronic lung disease[J]. Arch Dis Child, 2001, 84: F9－13.
|
|
47 Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short－ and long－term morbidity in very low birth weight infants[J]. Cochrane Database Syst Rev, 2007, (4): CD000501.
|
|
48 Brion LP, Bell EF, Rughuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants[J]. Cochrane Database Syst Rev, 2003, (4): CD003665.
|
|
49 Suresh G, Davis JM, Soll R. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated infants[J]. Cochrane Database Syst Rev, 2001, CD001968.
|
|
50 Ng GY, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants[J]. Cochrane Database Syst Rev, 2001, (3): CD003214.
|
|
51 Wilkie RA, Bryan MH. Effect of bronchodilators on airway resistance in ventilator－dependent neonates with chronic lung disease[J]. J Pediatr, 1987, 111: 278－282.
|
|
52 Brundage KL, Mohsini KG, Froese AB, et al. Bronchodilator response to ipratropium bromide in infants with bronchpulmonary dysplasia[J]. Am Rev Respir Dis, 1990, 142: 1137－1142.
|
|
53 Yuksel B, Greenough A. Ipratropium bromide for symptomatic preterm infants[J]. Eur J Pediatr, 1991, 150: 854－857.
|
|
54 Brion LP, Soll RF. Diuretics for respiratory distress syndrome in premature infants[J]. Cochrane Database Syst Rev, 2001, CD001454.
|
|
55 Schmidt B, Davis P, Moddemann D, et al. Long term effects of indomethacin prophylaxis in extremely－low－birth weight infants[J]. N Engl J Med, 2001, 344: 1966－1972.
|
|
56 Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants[J]. Cochrane Database Syst Rev, 2002, CD000174.
|
|
57 Howlett A, Ohlsson A. Inositol for respiratory distress syndrome in preterm infants[J]. Cochrane Database Syst Rev, 2003, CD000366.
|
|
58 Mabanta CG, Pryhuber GS，Weinburg GA, et al. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at high risk for, or colonised or infected with Ureaplasma urealyticum[J]. Cochrane Database Syst Rev, 2003, CD003744.
|
|
59 The STOP－ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP－ROP), a randomized, controlled trial. I: primary outcomes[J]. Pediatrics, 2000, 105: 295－310.
|
|
60 Askie LM, Henderson－Smart DJ, Irwig L, et al. Oxygen－saturation targets and outcomes in extremely preterm infants[J]. N Engl J Med, 2003, 349: 959－967.
|
|
61 Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease[J]. Cochrane Database Syst Rev, 2002, CD001453.
|
|
62 Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease[J]. Cochrane Database Syst Rev, 2006, CD001694.
|
|
63 Brion LP, Primhak RA, Ambrosio－Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease[J]. Cochrane Database Syst Rev, 2002, CD001817.
|
|
64 Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: Effect modification by risk for chronic lung disease[J]. Pediatrics, 2005, 115: 655－661.
|
|
65 Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroid for the treatment of chronic lung disease in ventilated very low birth weight preterm infants[J]. Cochrane Database Syst Rev, 2007, CD002057.
|
|
66 Ladha F, Bonnet S, Eaton F. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia－induced lung injury[J]. Am J Respir Crit Care Med, 2005, 172: 750－756.
|
|
67 Lai NM, Rajadurai SV, Tan K. Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/chronic lung disease[J]. Cochrane Database Syst Rev, 2006, CD005093.
|